Professor Bertil Andersson, Chief Executive of the ESF, called the two-day event that took place on 14-15 December in the capital city of Finland “an experiment” to bring together researchers and various types of funders from across Europe. High-level representatives from public/private funding foundations, research funding organisations, national innovation agencies, academies, intergovernmental agencies and the bioscience industry participated in the event which was kicked off by the Finnish Minister of Social Affairs and Health, Tuula Haatainen.
“We are now setting the ball rolling and there needs to be follow-up action,” Professor Andersson told the audience. The next EuroBioForum is scheduled to take place in Lisbon, Portugal on 15-16 November 2007.
In his remarks about life sciences in Europe to the some 160 participants, Professor Andersson recommended there should be a higher degree of coordination between national public funders and those who are working at the European level. He also mentioned joint efforts among various types of life sciences funders and the need for a coordinated/stronger strategy for research infrastructure in Europe.
He noted that Europe needs to be more competitive with the US and Asia. Currently R & D investment is fragmented among numerous funding bodies across Europe. It continues to lag behind Asia and the US in research funding, a fact that many observers warn is crippling the region's economic competitiveness. Efforts to correct this imbalance are urgently needed. EuroBioForum is expected to increase Europe's scientific presence and stimulate research and technology development in the life sciences field.
During the conference, 10 research consortia presented their pioneering research programmes on topics ranging from the production of hydrogen via artificial photosynthesis (SOLAR-H) to learning how to survive without water (DryLife).
EuroNanoPAR (European Nanomaterial Proactive Assessment of Risk) which is headed by Professor Vicki Stone from Napier University’s Centre for Health and the Environment (Edinburgh) in the UK was one of the projects that was presented. The main aim of the project is “to develop and launch a self-sustaining business, offering advisory and testing services on all aspects of occupational, consumer and environmental health, for the European nanotechnology industry,” according to Stone. The five-year project is currently seeking €145 million in funding.
Another research project that was being showcased was METABOTECH. The project is aimed at coordinating European national research efforts in the area of metabolomics - the quantitative and qualitative analysis of small molecules in cells, tissues and body fluids. Metabolic profiles are indicative of changes in metabolic pathways. Consequently, metabolomics is positioned to identifying treatment targets in diseases such as cardiovascular disease, stroke, obesity, diabetes, and depression.
“EuroBioForum offers several options to researchers like me,” commented Professor Thomas Hankemeier from the Leiden Amsterdam Center for Drug Research of the Leiden University in the Netherlands who is the head of the METABOTECH project.
“It helps me to establish contacts with other parties and explore potential funding options.”
Besides match making between funders and researchers, EuroBioForum has also invited experts to discuss opportunities and challenges for the life science field. One of the topics of discussion was the promotion of Systems Biology in Europe.
Professor Rudolf Aebersold from the Institute for Molecular Systems Biology, ETH Zurich told participants that the field of System Biology is in need of new data collection technologies if it wants to deliver its promise to society. The field is expected to generate “great opportunities” for researchers, Aebersold added. On the other hand, Adriano Henney; the Director of Global Discovery Enabling Capabilities & Science at AstraZeneca, pointed out that there are still a lot of challenges ahead for the Systems Biology field such as the rising cost of R&D, the challenging of regulatory environment and the fierce competitive market for drugs development.
Wouter Spek, EuroBioFund Director commented “Crosslinking of networks and bridging the gap between research and public/private funders is our main goal and there is still room for improvement in Europe. This first EuroBioForum has been an interesting and stimulating two-days and follow-up actions to develop several of the research consortia presented have already been planned. I We are definitely going to facilitate this in 2007.”
EuroBioFund, which was launched in June 2006, is aimed "to promote and coordinate interaction among European life sciences researchers and funders." The coordinating body has three key objectives. The first of these is to provide a platform for funding organisations and life science researchers to foster joint research initiatives through networking and brokerage. The second goal is to help organise research communities and facilitate "bottom-up" Europe-wide research programs, via the newly-formed EuroBioGenerator. Finally, the EuroBioFund is charged with shaping "a new funding way in Europe by helping to develop joint investments and funding of life sciences research," through the establishment of EuroBioAccess.
The European Science Foundation (ESF) provides a platform for its Member Organisations to advance European research and explore new directions for research at the European level. Established in 1974 as an independent non-governmental organisation, the ESF currently serves 78 Member Organisations across 30 countries.
Thomas Lau | alfa
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy